Abstract:FGF-21 has become a potential drug candidate for the treatment of type 2 diabetes. Previous studies have demonstrated that PEGylation of FGF-21 could significantly increase its in vivo half-life and provide its long-lasting blood glucose-lowering effect. To accelerate the development of PEGylated FGF-21 for clinical application as a long-acting antidiabetes drug, we prepared ahmFGF-21 (FGF-21 mutant) and PEGylated ahmFGF-21 in Escherichia coli Rosetta (DE3) by high cell density fermentation at a 50-L scale and pilot-scale purification. The physical and chemical properties of the purified proteins were analyzed in this study, including purity, molecular weight, isoelectric point, bacterial endotoxin, PEGylated site and second structure. As well as the in vitro glucose uptake activity and in vivo anti-diabetic effect were evaluated. Under the optimal fermentation and purification conditions, the average bacterial yield and expression level of target protein of three batches attained 52.2±4.6g/L and 223.92±5.41mg/L, respectively. The purity of pilot product was above 98% by SDS-PAGE (non-reducing or reducing) and HPLC (SEC or RPC) analysis and the final yield of PEGylated ahmFGF-21 was 87.91±1.49mg/L, which indicated that the pilot-scale production process was relatively stable. N-terminal sequencing and circular dichroism (CD) spectroscopy results showed that modification site of PEGylated ahmFGF-21 was alanine at N-terminal and the second structure of ahmFGF-21 had no obvious changes after PEGylation. Compared with ahmFGF-21, the long-acting hypoglycemic effect of PEGylated ahmFGF-21 prepared in the pilot-scale production was significantly improved in type 2 diabetic db/db mice. Our results demonstrated that the pilot-scale production process of PEGylated ahmFGF-21 was successfully established, which was very important for the clinical application.

Enhancement of FGF21 Expression by Site-Directed Mutagenesis

Optimization and Characterization of a Novel FGF21 Mutant

Utilization of SUMO Expression Vector to Efficiently Express Mouse FGF-21 and Studying of Its Bioactivity

Large-Scale Expression, Purification, and Glucose Uptake Activity of Recombinant Human Fgf21 in Escherichia Coli

Stability and Glucose Regulation of FGF21 after Modified with Arginines*

[Efficient Expression of Soluble Human FGF-21 and Its Glucose Regulation Activity].

Soluble Expression and Preparation of Recombinant Human Fibroblast Growth Factor 21 in E.coli

[Improvement of Yield and Purity of Human Fibroblast Growth Factor-21].

[Expression and Pharmacological Evaluation of Fusion Protein FGF21-L-Fc].

Expression of Recombinant H-Fgf21 in Periplasmic Space of Escherichia Coli

[Cloning, Expression and Glucose Regulation Activity of Human FGF-21].

Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21

Cloning, expression and glucose regulation activity of human FGF-21 HOU Yu-Ting, LI Jin-Nan, REN Gui-Ping, LIU Ming-Yao, SUN Guo-Peng, WANG Wen-Fei, LI De-Shan

Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation

SUMO fusion system facilitates soluble expression and high production of bioactive human fibroblast growth factor 23 (FGF23)

Pilot-scale Production and Characterization of PEGylated Human FGF-21 Analog.

Establishment of a Novel Method for Rapid Screening of Eukaryotic Cell Lines Stably Expressing High Level FGF-21

High-Level Soluble Expression of Higf-1 Fusion Protein in Recombinant Escherichia Coli

Prokaryotic soluble expression and purification of bioactive human fibroblast growth factor 21 using maltose-binding protein

Examination of Alternate Codon Bias Solutions for Expression and Purification of Recombinant Mechano-Growth Factor in Escherichia Coli.

Design and characterization of a FGF1‐FGF21 chimeric protein with increased stability and enhanced antidiabetic activities